文献速递核素与放射性配体治疗肿瘤 PET/CT

[212Pb]Pb-DOTAM-GRPR1用于前列腺肿瘤模型肽受体放射性核素治疗的临床前研究

Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model.
PubMed 文献 · J Nucl Med · 2024-11-01

本研究在前列腺肿瘤小鼠模型中评估了α粒子发生器212Pb标记的GRPR靶向肽[212Pb]Pb-DOTAM-GRPR1的药代动力学、毒性、辐射剂量学与疗效。结果显示肿瘤靶向可达每克5%注射剂量并持续24小时,肾脏为剂量限制器官,无毒剂量可达1,665 kBq。疗效研究中对照组中位生存9周,接受4次370 kBq(间隔3周)治疗组为19周,作者认为值得进一步临床试验探索。

要点

  • [212Pb]Pb-DOTAM-GRPR1在小鼠前列腺肿瘤中24小时内肿瘤摄取可达每克5%注射剂量。
  • 肽量从28 ng增至280 ng可降低脱靶摄取,尤其胰腺水平约降低30%。
  • 剂量学确认肾脏为剂量限制器官;毒性研究显示无毒剂量可达1,665 kBq。

核心结论

  • 综合数据表明[212Pb]Pb-DOTAM-GRPR1具有安全性、耐受性和疗效,值得进一步临床试验探索。

研究设计与样本

  • 在GRPR阳性前列腺肿瘤荷瘤小鼠中静脉给予[212Pb]Pb-DOTAM-GRPR1后评估药代动力学、毒性、辐射剂量学和疗效的临床前研究。

主要发现

  • 临床前研究显示24小时内肿瘤靶向可达每克5%注射剂量。
  • 药物制剂和用量优化分别使氧化和脱靶结合最小化。
  • 肽量从28 ng增至280 ng使脱靶摄取降低,尤其胰腺水平约降低30%。
  • 剂量学研究确认肾脏为剂量限制器官。
  • 毒性研究显示小鼠可注射的无毒剂量可达1,665 kBq。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论提出值得进一步临床试验探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of gastrin-releasing peptide receptor (GRPR) in various diseases, including cancer, has been extensively studied and has emerged as a promising therapeutic target. In this study, we successfully achieved the use of [212Pb]Pb-DOTAM-GRPR1, comprising the α-particle generator, 212Pb, combined with a GRPR-targeting peptide, GRPR1, in a prostate cancer model. Methods: Pharmacokinetics, toxicity, radiation dosimetry, and efficacy were assessed in GRPR-positive prostate tumor-bearing mice after intravenous administration of [212Pb]Pb-DOTAM-GRPR1 (where DOTAM is 1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane). Results: Preclinical studies have shown tumor targeting of up to 5 percent injected dose per gram over 24 h, and optimization of the drug formulation and quantity has led to minimized oxidation and off-target binding, respectively. Particularly, an increase in peptide amount from 28 to 280 ng was shown to reduce off-target uptake, especially at the level of the pancreas, by about 30%. Furthermore, dosimetry studies confirmed the kidney as the dose-limiting organ, and toxicity studies revealed that a nontoxic dose of up to 1,665 kBq could be injected into mice. Efficacy studies indicated a median survival time of 9 wk in the control group, which received only a buffer solution, compared with 19 wk in the group that received 4 injections of 370 kBq at 3-wk intervals. Conclusion: Taken together, these combined data demonstrate the safety, tolerability, and efficacy of [212Pb]Pb-DOTAM-GRPR1, thus warranting further exploration in clinical trials.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Saidi A, Stallons TA, Wong AG, et al. Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model. J Nucl Med. 2024. PMID: 39327021. doi:10.2967/jnumed.124.268101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。